股票骗局有哪些-中信证券app-【东方资本】,a股交易t 几,t0开通条件,专业线上配资

<form id="bhkcp"></form>

<tbody id="bhkcp"><strong id="bhkcp"></strong></tbody>

<tt id="bhkcp"><input id="bhkcp"></input></tt>

<blockquote id="bhkcp"></blockquote>

<menu id="bhkcp"></menu>

科學文獻

我們與學術機構開展合作研究，以評估我們的管線產品。以下是發表的相關文獻。

年：

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Kwee Yong, Hermann Einsele, Jordan M Schecter, Tito Roc […]

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2

Rui Liu, Gongzhizi Gao, Hongli Chen, Ruijun Dong, Wangg […]

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

María-Victoria Mateos, Katja Weisel, Valerio De Stefano […]

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison

Noffar Bar, Joris Diels, Suzy van Sanden, Jo?o Mendes, […]

Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

Winfried Alsdorf, Joris Diels, Francesca Ghilotti, Jo?o […]

本網站使用Cookies來改善您的整體體驗，讓您下次訪問網站時更加輕松快捷，為您帶來更好的服務。具體內容請參閱隱私政策 Cookie政策。

<option id="clllm"></option>

<option id="clllm"><pre id="clllm"></pre></option>

<ol id="clllm"></ol>

<ol id="clllm"></ol>

<center id="clllm"></center>